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fast-acting neurotransmitter. However, both studies owe a great 
debt to murine models of hyperekplexia which revealed key can-
didate genes for the human screening programme (Becker et al., 
1992; Buckwalter et al., 1994; Kingsmore et al., 1994; Mülhardt 
et al., 1994; Ryan et al., 1994; Gomeza et al., 2003a). Screening of 
genes encoding additional postsynaptic proteins involved in GlyR-
mediated transmission including the GlyR β subunit (GLRB; Rees 
et al., 2002), gephyrin (GPHN; Rees et al., 2003) and collybistin 
(ARHGEF9; Harvey et al., 2004) has revealed only single individu-
als with potential mutations in these genes. Although mutations 
in GLRB are a clear cause of exaggerated startle in humans and 
animals (Kingsmore et al., 1994; Mülhardt et al., 1994; Rees et al., 
2002; Hirata et al., 2005), deletions in GPHN have been associ-
ated with molybdenum co-factor defi ciency (Reiss et al., 2001), 
whilst gene rearrangements in ARHGEF9, encoding the RhoGEF 
collybistin are more commonly associated with X-linked mental 
retardation(Harvey et al., 2008b; Marco et al., 2008; Kalscheuer 
et al., 2009). Despite our successes in disease gene discovery, 
approximately 35% of the hyperekplexia patients we recruited 
to our cohort studies are devoid of mutations in genes encod-
ing postsynaptic GlyRs, associated proteins and the presynaptic 
transporter GlyT2. Although our knowledge of the proteomics 
of glycinergic synapses is extremely limited, this suggests that 
other genes encoding presynaptic transporters or receptor/trans-
porter-associated proteins are suitable candidates for mutation 
INTRODUCTION TO HYPEREKPLEXIA
Glycine receptors (GlyR) are heteropentameric ligand-gated 
 chloride ion channels that facilitate fast inhibitory neurotransmis-
sion in the human central nervous system (CNS) (Lynch, 2009). In 
humans, GlyRs have four functional subunits, GlyR α1–α3 and β 
that exist in heteromeric αβ combinations although the exact stoi-
chiometry is a matter of intense debate (Grudzinska et al., 2005). 
Dysfunction of inhibitory glycinergic neurotransmission causes 
startle disease/hyperekplexia in humans (OMIM 149400), char-
acterised by neonatal hypertonia and an exaggerated startle refl ex 
in response to tactile or acoustic stimuli. In some instances, this 
can result in life-threatening infantile apnoea episodes. The most 
common disease-causing genes are those encoding the postsynaptic 
GlyR α1 subunit (GLRA1) on chromosome 5q33.1 (Shiang et al., 
1993, 1995; Rees et al., 1994, 2001) and the presynaptic glycine 
transporter GlyT2 (SLC6A5) on chromosome 11p15.2 (Eulenburg 
et al., 2006; Rees et al., 2006). Both disease loci have revealed dozens 
of pathogenic missense, nonsense and frameshift mutations that 
can be inherited in either a dominant or recessive manner, with 
several recurrent mutations in GLRA1 (Figure 1).
The description of mutations in the GlyR α1 subunit gene by 
Shiang et al. (1993) was the fi rst channelopathy associated with 
ligand-gated chloride channels, whilst the mutations in the GlyT2 
gene reported by Rees et al. (2006) defi ned the fi rst neurological 
disorder linked to a defect in presynaptic transporter for a classical 
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screening in hyperekplexia. In this review, we describe the genetic 
 screening/structure-function approaches utilised in our collabo-
rative group to study hyperekplexia, and discuss future genetic 
screening approaches for the analysis of this genetically heterog-
enous neurological disorder.
CLINICAL ASCERTAINMENT OF HYPEREKPLEXIA PATIENTS
Since 1994, we have received over 260 referrals from clinicians located 
world-wide to perform genetic testing for hyperekplexia. This is 
currently performed at the Molecular Neuroscience Laboratory 
within the Institute of Life Science at Swansea University1. Once an 
anonymous patient clinical summary is received from the referring 
clinician, data is reviewed by a research committee with a view to 
assessing whether the patient phenotype fulfi ls the clinical criteria 
for mutation screening (Figure 1).
Alternative diagnoses could include paroxysmal extreme pain 
disorder, startle epilepsy or acquired(autoimmune) hyperekplexia. 
If the clinical data is suggestive of inherited hyperekplexia then a 
study information sheet, consent form and clinical pro-forma are 
issued to the referring clinician. If the patient and/or their family 
wish to pursue genetic testing on a research basis, then the referring 
clinician will obtain consent and collect a blood sample. The com-
pleted consent form and clinical pro-forma are then returned to the 
research team along with the blood sample, which is marked with 
a unique identifi er and transferred for extraction of genomic DNA 
for mutation screening. Details from the clinical pro-forma are then 
incorporated into an anonymous dataset to allow the  capture of 
standardised clinical information for each hyperekplexia sample 
received. The clinical pro-forma, along with evidence of consent, 
is stored securely on-site at ILS Swansea.
Since new UK-based ethical approval was confi rmed in 
June 2006 (previous ethical approval in Cardiff University, UK, 
1994–1999 and Auckland University, New Zealand, 2000–2006), 
41 index patient samples have been accepted for hyperekplexia 
mutation screening and another 11 are currently undergoing 
the validation/ascertainment. An additional, 13 familial samples 
have been received for cascade screening – samples which require 
verifi cation of identifi ed mutations in close relatives. Testing of 
parental samples of index cases also enables confi rmation of the 
origin of mutations in cases where compound heterozygosity 
is suspected.
There are potential risks associated with running an international 
genetic screening service in this way. Since clinical observations are 
essential to describe the phenotype of the patients referred to our 
laboratory, we are dependent upon the detail of information pro-
vided by the referring clinicians. Occasionally we receive messages 
from families, index cases and carers where they have received a 
clinical diagnosis of hyperekplexia. We strongly believe that giving a 
genetic diagnosis in the absence of genetic counselling is bad prac-
tice, so we encourage these individuals to make contact with us via 
a clinical referral.
CLINICAL PHENOTYPING OF HYPEREKPLEXIA PATIENTS
Deciding which patient samples to screen can be challenging. 
If entry criteria are too narrow then the phenotype is never 
expanded, too broad and the service can be overwhelmed and 
yet not produce valuable results (see Table 1). Hyperekplexia is 
almost certainly a rare condition, but of unknown prevalence 
and the true phenotype is complicated by cases which report 
association with co-morbid conditions such as sudden infant 
death (Giacoia and Ryan, 1994), epilepsy (Lerman-Sagie et al., 
2004), abdominal herniae (Eppright and Mayhew, 2007) or devel-
opmental delay (Praveen et al., 2001). The early descriptions of 
hyperekplexia focussed on the shared clinical features (stiffness, 
startle and falls), the hereditary nature of the condition and the 
degree of phenotypic variability (which were qualifi ed as ‘major’ 
and ‘minor’ variants) (Kirstein and Silfverskiold, 1958; Kok and 
Bruyn, 1962). Although many cases were autosomal dominant, 
this is not exclusively the case and this misconception represents a 
bias towards studying large families with many affected members 
(Rees et al., 1994; Masri and Hamamy, 2007). A useful sign par-
ticularly in neonatal hyperekplexia (occasionally seen in cerebral 
palsy) is the nose-tap response: the root of the nose is lightly 
tapped, provoking a brief and involuntary backwards-retraction 
of the head.
Neonatal apnoea episodes show an important and potentially 
life- threatening association with hyperekplexia. These are parox-
ysmal attacks of abdominal hypertonia with resulting hypoxia. It is 
important that parents are therefore taught the Vigevano manoeu-
vre (fl exing of the head and limbs toward the trunk) which coun-
teracts these attacks (Vigevano et al., 1989). Whether these hypoxic 
spells are related to simple intercostal muscle stiffness, brainstem 
abnormalities or developmental delay remains unknown.
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FIGURE 1 | Molecular genetic screening pipeline. This schematic diagram 
highlights the key stages involved in the clinical ascertainment and molecular 
genetic diagnosis.
1www.swan.ac.uk/ils
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reported from Polynesia (see Figure 2). This may be of impor-
tance, since there are certain cultural neuropsychiatric conditions 
such as the ‘Jumping Frenchmen of Maine’ and ‘Latah Syndrome’, 
which share some characteristics with hereditary hyperek-
plexia (Kurczynski, 1983). Whether these conditions represent 
the  exaggerated startle described in certain anxiety conditions 
is unknown, since some investigators describe these cultural 
startle conditions as predominantly psychosomatic in nature 
(Bartholomew, 1994). Exaggerated startle may also be second-
ary to predominately pontine pathology: brainstem infarction, 
infection, haemorrhage or hypoxia can all produce hyperekplexia-
like symptoms. In addition, individuals with paraneoplastic syn-
dromes, multisystem atrophy and multiple sclerosis can all exhibit 
exaggerated startle responses (Bakker et al., 2006).
MOLECULAR GENETICS OF HYPEREKPLEXIA
The most common genetic causes of human hyperekplexia are 
mutations in the GlyR α1 subunit (GLRA1) and GlyT2 (SLC6A5) 
genes (see Harvey et al., 2008b for a review and comprehensive 
mutation data). Therefore, new patient samples that conform 
to our diagnostic criteria are analysed by PCR amplifi cation of 
individual exons and dideoxy DNA sequencing on an Applied 
Biosystems 3100 capillary sequencing platform to detect sequence 
variants in GLRA1 and SLC6A5 (Rees et al., 2006). For all candidate 
genes, analysis includes exons and fl anking splice branch points, 
donor and acceptor sequences, 5′ and 3′ untranslated regions and 
splice variants are derived insilico, using the Human Genome 
Browser at the University of California, Santa Cruz2. One future 
aim is also to capture sequence variants in the GLRA1 and SLC6A5 
gene promoters, although only the former has been character-
ised in any detail (Morris et al., 2004), and the minimal promoter 
encompasses 5.4 kb of sequence. A robust readout of promoter 
activity is also required in order to assess any detrimental effect 
of potential sequence variations. By contrast, GlyT2 transcripts 
are extensively alternatively spliced at the N-terminus (Ponce 
et al., 1998; Ebihara et al., 2004), and it is possible that multi-
ple tissue-specifi c or developmentally regulated promoters exist, 
complicating potential sequence analysis. Candidate genes with 
rare or as yet unknown mutation frequencies undergo medium-
throughput gene variation detection by analysing PCR amplimers 
with a high-resolution melting (HRM) platform (LightScanner, 
Idaho Technologies, USA). HRM is a highly-sensitive method of 
analysing genetic variations in short PCR amplicons generated in 
the presence of the saturating double-stranded DNA binding dye 
LCGreen® Plus (Idaho Technologies). The technique allows the 
PCR amplicons to be distinguished based on their dissociation 
during rapid melting (Figure 3). HRM analysis has a published 
detection rate of 100% for heterozygous mutations (Lonie et al., 
2006; Kennerson et al., 2007) and has the added advantages of 
high speed (∼15 min per 96 well plate run), no post-PCR han-
dling and greatly reduced costs (9 p per amplicon) compared to 
sequencing (∼£5 per read from commercial services)3. Thus, HRM 
allows for rapid and cost-effective mutation discovery in dsDNA 
Table 1 | Diagnostic criteria for human hyperekplexia.
REQUIRED CRITERIA
Startle: Exaggerated startle refl ex to unexpected auditory or tactile stimuli. 
The startle response can be prolonged and be present before birth. 
Consciousness is unaltered during startle episodes. Nose-tap test is positive 
and does not habituate
Stiffness: Generalized stiffness immediately after birth, normalising during 
the fi rst years of life. The stiffness can be predominantly truncal or lower 
limb, increases with handling and disappears during sleep. Short period of 
generalised stiffness following the startle response during which voluntary 
movements are impossible. This can result in falls in adults
Exclusion of mimics: Normal MR imaging, no dysmorphism or congenital 
defi cits noted. Normal EEG during startle episode. Autonomic features of 
paroxysmal extreme pain disorder absent
SUPPORTIVE CRITERIA
Inguinal, umbilical, or epigastric herniae
Congenital dislocation of the hip
Hypoxic attacks in infancy
THE EFFECT OF PHENOCOPY
Hyperekplexia is (not unsurprisingly) most commonly confused 
with seizure disorders (see Table 2) such as benign neonatal con-
vulsions. However, in hyperekplexia, consciousness is retained 
and there is no EEG correlate to either the startle or hypertonic 
 posturing. False positive results are reported, since exaggerated 
limb jerking can result in a degree of artefact on the EEG trace. 
However, symptomatic improvement is often seen with benzodi-
azepines such as clonazepam and less frequently with other anti-
convulsant drug therapies.
Despite the classical features being present from birth or even 
earlier (some reports suggest that exaggerated startle responses 
can be felt in utero (Badr El-Din, 1960; Dalla Bernardina et al., 
1988; Leventer et al., 1995) the majority of defi nitive diagnoses 
are made during infancy. A positive test in an infant can result 
in older family members receiving an explanation for previously 
unexplained symptoms. Alternatively, a proportion of early neo-
natal referrals with primary hypertonia can sometimes develop 
into more sinister degenerative disorders, which is not typical of 
inherited hyperekplexia and these cases are invariably negative 
for GlyR and GlyT2 mutations. However, we are also eager to 
differentiate between these early onset congenital cases and adult 
onset cases of hyperekplexia. Since autoimmunity to GlyRs has 
recently been found in a single case of acquired hyperekplexia 
(Hutchinson et al., 2008) we can now process samples from such 
individuals for testing for anti-GlyR or GlyT2 antibodies, using 
immortalised human cell lines expressing recombinant GlyRs 
or GlyTs. Hypertonia (predominantly in the lower limbs) is the 
key presenting feature of stiff-person syndrome, which is associ-
ated with either autoimmunity to gephyrin (Butler et al., 2000) 
orglutamic acid decarboxylase 65 (GAD65; Duddy and Baker, 
2009). Furthermore, attempts to defi nitively describe clinical 
symptoms and prevalence of hyperekplexia are challenged by 
potential referral bias. To our knowledge, hyperekplexia has not 
been diagnosed at the genetic level in people who are ethnically 
Slavic, South or Central American and very few cases have been 
2http://genome.ucsc.edu
3http://www.dnaseq.co.uk/
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with improved sensitivity compared to other screening platforms. 
However, limitations include the optimisation of amplifi cation 
conditions in the presence of LCGreen® Plus, limitations on the 
size of amplicons (<400bp) and non-specifi c amplicons or primer 
dimers signifi cantly reduce HRM performance. For a comprehen-
sive review of HRM see White and Potts (2006).
PCR products showing variant melting profi les suggestive of 
allelic heterogeneity undergo purifi cation and direct sequencing 
to identify the genetic variation. Population studies of genomic 
variation are performed using agarose gel restriction fragment 
length polymorphisms (RFLPs) to confi rm the absence of the 
mutation in the healthy population. This can also be confi rmed 
Table 2 | Clinical phenocopies of human hyperekplexia.
Phenocopy Comparisons with human startle
ACQUIRED HYPEREKPLEXIA
Sub-acute anti-glycine receptor antibody mediated condition  Similarities Truncal rigidity, muscle spasms and stimulus induced startle
that responds to immunosuppression and plasma exchange Differences Features not present from early life immunosuppression clearly
(Hutchinson et al., 2008) effi cacious. Apnoea attacks not described
PAROXYSMAL EXTREME PAIN DISORDER
Autosomal dominant condition recently shown to be a sodium  Similarities Onset in neonatal period or infancy, persists throughout life. Dramatic
channelopathy involving SCN9A (previously known as familial syncopes with bradycardia and sometimes asystole.
rectal pain syndrome; Fertleman et al., 2007) Tonic attacks are triggered by factors such as defecation, cold wind, eating, and 
 emotion
 Differences Autonomic manifestations predominate initially, with skin fl ushing
 in all and harlequin colour change. Later attacks of excruciating deep burning pain 
 often in the rectal, ocular, or jaw
JUMPING FRENCHMEN OF MAINE/LATAH SYNDROME
Culturally bound neuropsychiatric syndromes thought to be an  Similarities Excessive response to startle
anxiety/somatisation disorder (Meinck, 2006) Differences Echopraxia (involuntary repetition of another’s words or actions)
 and echolalia (repetitive vocalisations) 
STARTLE EPILEPSY
Startle epilepsy is a refl ex epileptic seizure precipitated by a  Similarities Surprising stimuli induce motor reactions – consciousness
sudden stimulus; most patients are young and have infantile can be preserved in seizures
cerebral hemiplegia (Meinck, 2006) Differences Neuro-imaging will almost certainly be abnormal
STIFF PERSON SYNDROME
Progressive axial stiffness and intermittent spasms mainly evoked  Similarities Stimulus induced hypertonia, startles and falls. 
by unexpected stimuli; associated with auto-antibodies Hypertonia can preferentially affect lower-limbs
to either gephyrin (Butler et al., 2000) or GAD (Meinck, 2006) Differences Stiffness/hypertonia is much more prolonged than
 the paroxysmal attacks seen in hyperekplexia
TOURETTE’S SYNDROME
Motor and vocal tics, associated with an exaggerated startle refl ex,  Similarities Startle response, symptoms precipitate by stressors
behaviour change and stereotypy (Bakker et al., 2006) Differences Vocalisations and obsessive/compulsive behaviours.
 Motor tics can be complex and appear semi-purposeful
CRISPONI SYNDROME
An autosomal recessive syndrome initially described in 12 different  Similarities Evident at birth. Marked muscular contraction of the facial
families in southern Sardinia; caused by mutations muscles in response to tactile stimuli or during crying, contractions
in the CRLF1 gene (Crisponi, 1996; Crisponi et al., 2007) slowly disappear as infant calms. Generalised seizures (albeit rare) and mild
 psychomotor delay in some. Low GABA levels in CSF have been described
 Differences Abundant salivation simulating a tetanic spasm. Neck muscle
 hypertonia. Facial anomalies (large face, chubby cheeks, broad nose with
 anteverted nostrils and long philtrum). Bilateral camptodactyly. Hyperthermia
SYMPTOMATIC STARTLE AND MYOCLONUS
Neuropsychiatric – anxiety states including generalised  Similarities Symptoms will be exaggerated by stressors. Stimulus sensitive
anxiety disorder, post traumatic stress disorder (e.g. touch) can be seen following hypoxic brain injury.
Cerebral – Children with cerebral palsy, post-traumatic or  Children with cerebral palsy may have a positive nose-tap test
hypoxic encephalopathy, para neoplastic syndromes Differences Acquired cause often clear, for example late adult onset of
Brainstem – particularly pontine patholog yeg  multi system atrophy. Hypertonia not a feature of anxiety syndromes
Multiple system atrophy (Bakker et al., 2006)
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(MutationSurveyor, SoftGenetics®, USA) which is particularly use-
ful for detecting homozygous changes in the sequence data. After 
this systematic analysis in our laboratory, 53 single,  unrelated, 
FIGURE 3 | Validation of the Light Scanner technology. To assess the 
application of this method we performed a series of validation assays utilising 
known genetic variations in the GLRA1 gene in a population of hyperekplexia 
patients. This screening method accurately detected all heterozygous (red and 
orange) and homozygous (blue) missense mutations present. The most common 
GLRA1 mutation associated with hyperekplexia, R271Q, is shown in red. The 
assay also detected a false-positive variant (green) generated due to the poor 
quality of amplifi ed PCR product. Population control samples are shown in grey.
FIGURE 2 | Global origin of hyperekplexia referrals. Upper panel: A geographical representation of the global origin of hyperekplexia patients recruited to our 
laboratory (red) and other laboratories (blue – Information obtained from the NCBI PubMed search engine). Lower panel: Detail showing the origin of patients 
recruited from central Europe.
byassessing HRM profi les of control DNA samples alongside a 
mutation-positive sample. DNA sequencing chromatograms are 
then assessed using an automated mutation surveyor programme 
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 sporadic cases of hyperekplexia have proved gene-negative in 
screening approaches for GLRA1, GLRB, GPHN, ARHGEF9 
and SLC6A5.
Both dominant and recessive mutations in GLRA1 are associ-
ated with sporadic and familial startle disease, whilst a proportion 
of sporadic hyperekplexia is accounted for by the homozygous 
 inheritance of recessive or compound heterozygous GLRA1 
 mutations (Rees et al., 2001). By contrast, the vast majority of 
mutations in SLC6A5 are inherited as compound heterozygotes 
or show recessive inheritance of a single mutation from con-
sanguineous parents. To date, there is only a single example of 
a dominant mutation in SLC6A5 (Rees et al., 2006). Hence, the 
parental carriers of SLC6A5 mutations are typically asymptomatic 
indicating that dominant negative effects are not a common muta-
tional  mechanism. Other explanations for a single mutation could 
include an undetected second-hit event, not easily detectable by 
PCR and sequencing. For example, promoter mutations, large 
deletions or intronic SNPs causing allelic dropout due to PCR 
primer mismatches are possible. Even synonymous SNPs that do 
not cause an amino acid substitution could cause creation of an 
ectopic splice donor or acceptor site, causing missplicing of gene 
transcripts. We have begun to assess these issues by using multi-
plex ligation-dependent probe amplifi cation (MLPA) analysis in 
index cases, to assay for possible deletions in SLC6A5 and GLRA1. 
MLPA provides the means for the quantitative analysis of various 
changes in gene structure and/or gene copy number of several 
dozens (40–50) of DNA targets in a single reaction containing 
small amounts (∼20ng) of human chromosomal DNA. Binary 
probes containing a sequence-specifi c part and a universal part are 
hybridized to their DNA targets and ligated. Each ligated probe is 
then PCR amplifi ed with a universal primer pair and gives rise to 
an amplicon of unique size. The relative amount of each amplicon 
refl ects the quantity of the corresponding target that is present in 
the nucleic acid sample. While allelic drop-out can be assessed 
by designing an additional primer set, changes in the promoter 
sequences and splicing patterns of GLRA1 and SLC6A5 are more 
challenging. In particular, we are also limited by the lack of patient-
specifi c RNA resource or the assurance that the genes are expressed 
in peripheral leukocytes. Affordable next generation re-sequencing 
(e.g. 454 Roche, Illumina Solexa, AB SOLiD) along with high-
throughput splicing assays may resolve these current limitations. 
These resources would also allow us to assess changes in RNA 
editing of GlyR transcripts, an important consideration for stud-
ies of GlyR α2 and α3 subunit genes in health and disease (Meier 
et al., 2005; Eichler et al., 2009).
MOLECULAR ANALYSIS OF POTENTIALLY 
PATHOGENIC MUTATIONS
Potentially disease-causing mutations can also be subjected to 
functional and molecular modelling analysis to provide insight 
into the precise mechanisms underlying pathogenicity. In the case 
of SLC6A5, mutations were analysed by homology modelling of 
GlyT2 using the crystal structure of the bacterial leucine trans-
porter (LeuT) (Yamashita et al., 2005). Simple sequence alignments 
of LeuT with GlyT1 and GlyT2 allowed us to identify residues 
potentially involved in coordinating glycine and Na+ binding (Rees 
et al., 2006), which were later confi rmed by assays on recombinant 
wild-type and mutant GlyT2 including [3H]glycine uptake assays, 
sophisticated electrophysiological analyses in Xenopus oocytes and 
molecular modelling (Rees et al., 2006; Harvey et al., 2008a).
Structural modelling is carried out using a homology modelling 
pipeline built with the Biskit structural bioinformatics platform 
(Grunberg et al., 2007). Our pipeline workfl ow incorporates the 
NCBI tools platform (Wheeler et al., 2007), including the BLAST 
program (Altschul et al., 1990) for similarity searching of sequence 
databases. Protein sequences corresponding to the Protein Databank 
of protein structures were searched for homology with the gene 
of interest in order to identify putative structural homologues. 
T-COFFEE (Notredame et al., 2000) was used for alignment of the 
test sequence with the template, followed by 10 iterations of the 
MODELLER homology modelling program (Eswar et al., 2003) 
(Figure 4).
FURTHER HYPEREKPLEXIA CANDIDATE GENES
Our recent research into glycinergic transmission has clearly dem-
onstrated the importance of both presynaptic (GlyT2) and postsyn-
aptic (GlyR α1β) mechanisms in health and disease. This work has 
also suggested that our search for other suitable candidate genes for 
mutation analysis in human hyperekplexia should be broadened 
(Table 3). Potential target genes are discussed below in the context 
of their putative roles in glycinergic synaptic physiology.
GlyT1
Whilst inhibitory glycinergic neurotransmission is dependent upon 
agonist-mediated activation of postsynaptic GlyRs, this function 
is dependent upon having a suffi cient pool of releasable glycine 
within the presynaptic terminal and prompt termination of gly-
cinergic transmission. GlyT1, encoded by SLC6A9 (1p34.1) fulfi ls 
the latter function, and is predominately expressed on glial cells. 
Studies on GlyT1 knockout mice (Gomeza et al., 2003b; Tsai et al., 
2004) suggest that loss of function of GlyT1 results in a patho-
logical accumulation of synaptic glycine, causing severe motor 
defi cits and premature death as a result of respiratory failure. The 
phenotype of the GlyT1 knockout mouse resembles a devastating 
neurological disorder known as glycine encephalopathy (OMIM 
605899) although no SLC6A9 mutations have been found to date 
in this disorder in humans. However, it is possible that more subtle 
missense mutations could result in a gain of function of GlyT1, 
causing enhanced clearance of glycine from the synaptic cleft into 
neighbouring glial cells. This could cause depletion of glycine in 
neighbouring presynaptic neurones, which may result in hyperek-
plexia in humans (Harvey et al., 2008a).
GlyT2 INTERACTORS
Further presynaptic candidates for genetic analysis include proteins 
interacting with GlyT2, such as syntenin-1 and ULIP6. ULIP6 is 
encoded by DPYSL5 (2p23.3) and is a brain-specifi c phosphopro-
tein of the Ulip/collapsing response mediator protein family. ULIP6 
interacts with extended intracellular N-terminus of GlyT2 in a phos-
phorylation dependent manner (Horiuchi et al., 2005). Since ULIP6 
has been implicated in GlyT2 endocytosis and recycling (Eulenburg 
et al., 2005; Horiuchi et al., 2005), it is plausible that mutations in 
ULIP6 could cause hyperekplexia by altering levels of presynaptic 
GlyT2. By contrast, the PDZ containing  protein  syntenin-1, encoded 
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FIGURE 4 | Structural modelling of human GlyT2. The wild-type (A) and 
the S510R mutant (B) model were generated based on homology with the 
crystal structure of LeuT, a bacterial Na+/Cl−-dependent neurotransmitter 
transporter homologue (PDB: 2A65). The models cover residues 191–754 
of GlyT2 and show the position of the S510R mutation in TM7 along with 
the extensive re-arrangement of other transmembrane regions in the 
S510R that results in defective membrane traffi cking of S510R and 
trapping of wild-type GlyT2 (see Rees et al., 2006). Models were visualized 
using the molecular graphics program Chimera (http://www.cgl.ucsf.edu/
chimera/).
Table 3 | Candidate genes for mutation screening in hyperekplexia. 
Chromosomal locations were obtained from http://ncbi.nlm.nih.gov/
Candidate gene Location Protein Proposed role at
   glycinergic synapse
SLC6A9 1p34.1 GlyT1 Termination of glycinergic
   neurotransmission by
   uptake into glial cells
SLC32A1 20q11.23 VIAAT Vesicular transport of GABA
   and glycine
SLC6A17 1p13.3 NTT4 Vesicular transport of glycine
DPYSL5 2p23.3 ULIP6 GlyT2 interacting protein
SDCBP 8q12.1 Syntenin-1 GlyT2 interacting protein
by the gene SDCBP (8q12.1) is thought to regulate the traffi cking 
or presynaptic localisation of GlyT2 in glycinergic neurones (Ohno 
et al., 2004). Mutations that affect syntenin PDZ binding domains 
could cause mislocalisation of GlyT2 and other interacting partners, 
since GlyT2 localisation in the presynaptic terminal is dependent on 
the C-terminal PDZ binding motif (Armsen et al., 2007). However, 
due to the wide range of proteins interacting with syntenin-1, we 
consider it unlikely that defects in syntenin-1 will give rise to clas-
sical hyperekplexia (Harvey et al., 2008b).
VIAAT
Another obvious hyperekplexia candidate gene is the vesicular 
inhibitory amino acid transporter (VIAAT), encoded by SLC32A1 
(20q11.23). VIAAT is expressed in both GABAergic and  glycinergic 
neurones (Chaudhry et al., 1998), and is responsible for the 
 chloride-dependent loading of presynaptic vesicles with GABA and 
glycine (Jin et al., 2003; Juge et al., 2009). We suggest that certain 
mutations in VIAAT could lead to the specifi c loss of glycine (but 
not GABA) loading into synaptic vesicles, thus resulting in hyper-
ekplexia. VIAAT was fi rst identifi ed as a mammalian homologue of 
the ‘uncoordinated’ C. elegans mutant unc-47, which was known to 
be defective in a presynaptic component of GABA release. Despite 
the fact that C. elegans do not appear to use glycine as a neuro-
transmitter, in a sophisticated cellular assay Aubrey et al. (2007) 
were able to show that UNC-47 is able to readily transport both 
GABA and glycine into vesicles. Importantly, the UNC-47 mutation 
G462R was shown to abolish GABA, but not glycine uptake. Since 
residue G462 is conserved at the equivalent position (G500) in 
rodent and human VIAAT sequences, mutations in SLC32A1 could 
theoretically compromise GABA uptake into synaptic vesicles while 
leaving glycine uptake intact. Since it is clearly possible to separate 
GABA and glycine transport by a single missense mutation, our 
hypothesis is that other missense mutations could also result in a 
GABA-specifi c VIAAT, potentially resulting in hyperekplexia.
NTT4
The orphan transporter NTT4 (also known as Rxt1), encoded by 
SLC6A17 (1p13.3) has recently been implicated as a vesicular trans-
porter for glycine, proline, leucine and alanine (Parra et al., 2008). 
This novel fi nding suggests that NTT4, which is highly expressed 
in several brain regions, including the spinal cord (Liu et al., 1993), 
may have an important role in glycinergic transmission and pos-
sibly hyperekplexia.
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THE FUTURE – PHENOTYPING, GENOMIC AND 
PROTEOMIC REVOLUTION
Despite the advances in the molecular genetics of hyperekplexia 
of the last 20 years, we are no closer to describing certain clinical 
aspects than the original pioneering study by Andermann et al. 
(1980). Hyperekplexia is rare, easily misdiagnosed and clonazepam 
is still the current treatment of choice. We have been unable to fi nd 
a genetic basis to the original delineation – the so called ‘major’ 
and ‘minor’ variants. Collections of large cohorts, particularly con-
taining sporadic cases may help us move away from the inherent 
bias caused by studying large families with a single gene mutation. 
Future challenges include improving testing turnaround times and 
accessibility, and collecting comprehensive clinical data to improve 
our understanding of possible differences in clinical phenotypes 
caused by mutations in GLRA1 versus SLC6A5. This will also enable 
us to identify potential hyperekplexia-associated co-morbidities 
and identify potential phenocopy referrals.
On the horizon is the prospect of third generation sequence 
platforms which will facilitate automated re-sequencing of large 
genomic segments containing disease-causing genes and new can-
didate loci and possibly even whole genomes of affected individuals. 
These include the pyrosequencing-based platform of next gen-
eration 454 sequencing (see Rothberg and Leamon, 2008) which 
was recently used for rapid genome re-sequencing of an individual 
genome at a fraction of the cost of previous platforms (Wheeler 
et al., 2008). Such coverage will provide not only the sequence of 
coding exons and fl anking spice sites, but information on intra-
genic DNA, SNP haplotype risk factors and copy number variables. 
Affordability is at present the main barrier and as a medium-term 
solution enrichment of individual chromosomal regions  containing 
GLRA1 and SLC6A5 may provide an interim solution. For  example, 
Zheng and colleagues have recently developed a method for high-
throughput variant detection, utilising specifi c genomic regions 
for target amplifi cation by capture and ligation (TACL), allele 
enrichment and array resequencing (Zheng et al., 2009). This plat-
form has identifi ed rare and novel variants, and will undoubtedly 
lead to improvements in our understanding of complex genetic 
disorders.
Molecular biology, animal models of glycinergic function and 
detailed proteomic studies will continue to provide further can-
didates for genetic screening in hyperekplexia and other poten-
tial disorders of glycinergic synapses. The new targets described 
above are being screened at present in patients lacking mutations 
in GLRA1 and SLC6A5. Molecular genetic studies of unresolved 
ENU-induced mutations in zebrafi sh (Granato et al., 1996) may 
also tease out novel determinants of glycinergic function (Hirata 
et al., 2010). These leads suggest that new genes of major effect 
could shortly join GLRA1 and SLC6A5 in our molecular screening 
programme.
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